Shandong Boan Biotechnology Co., Ltd. (FRA:UJ9)

Market Cap	453.13M -18.6%
Revenue (ttm)	95.57M +8.1%
Net Income	869.92K -90.2%
EPS	0.00 -90.9%
Shares Out	n/a
PE Ratio	520.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	20
Open	0.7050
Previous Close	0.6900
Day's Range	0.7050 - 0.7050
52-Week Range	0.6650 - 2.1200
Beta	n/a
RSI	39.49
Earnings Date	Mar 30, 2026

About FRA:UJ9

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 714
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UJ9

Financial Performance

In 2025, FRA:UJ9's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY